Walsh, Sharon L.
Comer, Sandra D.
Zdovc, Jurij Aguiar
Sarr, Céline
Björnsson, Marcus
Strandgården, Kerstin
Hjelmström, Peter http://orcid.org/0000-0001-6422-284X
Tiberg, Fredrik
Funding for this research was provided by:
Camurus AB
Article History
Received: 9 November 2022
Revised: 14 December 2023
Accepted: 19 December 2023
First Online: 10 January 2024
Competing interests
: SW: has received consultant fees for advising on the development of products for the treatment of opioid use disorder from Arbor Pharmaceuticals, AstraZeneca, Brainsway, Cerevel, Pocket Naloxone, and Titan Pharmaceuticals in the past three years. SC: Within the past three years, SC has received research funding from Alkermes, BioXcel, Go Medical, Intra-cellular Therapies, Janssen, and Lyndra. SC has also consulted for Alkermes, Mallinckrodt, Nektar, Opiant, and Otsuka. CS, MB, and JAZ: Employees of Pharmetheus, who were contracted to perform the analysis. KS and PH: Employees of Camurus AB at time of study. FT: Current employee of Camurus AB. Camurus AB supported with development of this study.
: All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.